Beyond Air, Inc.XAIRReports Wed, Nov 11 · Quarter Ended September 30, 2026
Health Care · Health Care Equipment & Services · NASDAQ · United States · beyondair.net
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.
Key ratios
FCF / Sales
-255.0%TTM
2026
-249.6%2025
-1190.3%2024
-5328.7%
ROA
-57.5%TTM
2026
-55.5%2025
-64.0%2024
-62.7%
ROE
-519.5%TTM
2026
-334.1%2025
-233.5%2024
-185.8%
Revenue growth
60.8%TTM
2026
107.3%2025
219.7%
Recent news
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Track XAIR in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer